Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus PHENERGAN VC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL PRESERVATIVE FREE versus PHENERGAN VC.
BENADRYL PRESERVATIVE FREE vs PHENERGAN VC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine competitively antagonizes histamine at H1-receptors on effector cells, leading to relief of allergic symptoms. It also possesses anticholinergic, antiemetic, sedative, and local anesthetic effects.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
25-50 mg IV/IM every 4-6 hours as needed; maximum single dose 100 mg, maximum daily dose 400 mg.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
None Documented
None Documented
Terminal elimination half-life: 4-8 hours (mean ~5 hours). Prolonged in hepatic impairment (up to 2-fold) and elderly (7-12 hours).
9-16 hours; prolonged in hepatic impairment.
Primarily renal (90% as metabolites and unchanged drug); ~1% excreted in feces via bile. Unchanged diphenhydramine accounts for <5% of urinary recovery.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination